Clinical Trial

Observational Study for SIR-Spheres Therapy for the Treatment of HCC Patients in China

Enrolling by Invitation
View on ClinicalTrials.gov →
Record status
This record was last updated December 5, 2024 (before its estimated December 31, 2024 completion). Its status may not reflect the trial's current state.
Summary
Yttrium-90 (y90) Microsphere Injection Solution was approved by the NMPA in 2022. Currently, there is a lack of summary of real-world data in China. Therefore, this retrospective real-world study is intented to explore the characteristics and efficacy of HCC patients treated with y90 in China, aiming to provide reference for guiding and optimizing clinical practices and subsequent confirmatory clinical studies for the treatment of HCC patients in China.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-11-26.
Trial Details
NCT Number NCT06712017
Lead Sponsor GrandPharma (China) Co., Ltd.
Conditions Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma Non-Resectable
Enrollment 100 participants
Start Date 2024-08-22
Primary Completion 2024-12-31 (estimated)
Study Completion 2025-06-30 (estimated)
Updated on ClinicalTrials.gov 2024-12-05